Home / FITY : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does FITY make money? Does FITY have pricing power? What's the Earnings Whisper? Will FITY profit more as the business scales? What is FITY's management track record? Is FITY's current price justified?

Fifty 1 Labs, Inc.

$0 -$0.00 (-66.67%)

OTC · 14 Sep 2026 15:38 UTC

Previous Close

Day Range

$0 - $0

Year Range

$0$0

Market Cap

114.38K

AVG Volume

17.01M

Trailing/Forward PE

-2.83/-

PEG ratio

-0.03

Dividend Yield

Next Earnings Date

Primary Exchange

Other OTC

Revenue (USD) · TTM

FITY Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
23 Q3	245.9K
23 Q2	245.53K
23 Q1	245.5K
22 Q4	92.12K
22 Q3	20.87K
22 Q2	29.12K
22 Q1	29.12K
21 Q4	18K
21 Q3	35.64K
21 Q2	40.39K

Net Income (USD) · TTM

FITY Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
23 Q3	-214.91K
23 Q2	-18.96K
23 Q1	-509.93K
22 Q4	-507.03K
22 Q3	-456.92K
22 Q2	-450.7K
22 Q1	35.05K
21 Q4	14.69K
21 Q3	-47.19K
21 Q2	-48.13K

Operating Income (USD) · TTM

FITY Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
23 Q3	-234.9K
23 Q2	-38.95K
23 Q1	-529.92K
22 Q4	-527.02K
22 Q3	-536.88K
22 Q2	-530.66K
22 Q1	-44.91K
21 Q4	-65.28K
21 Q3	-58.74K
21 Q2	-62.7K

EBITDA (USD) · TTM

FITY EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
23 Q3	-138.44K
23 Q2	57.51K
23 Q1	-347.39K
22 Q4	-386.07K
22 Q3	-450.81K
22 Q2	-444.6K
22 Q1	-44.91K
21 Q4	-65.28K
21 Q3	-58.74K
21 Q2	-62.7K

Cash Flows (USD) · TTM

FITY Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
23 Q3	307.98K
23 Q2	505.54K
23 Q1	14.57K
22 Q4	17.47K
10 Q3	-1.57M
10 Q2	-1.54M
10 Q1	-1.5M
09 Q4	-1.63M
09 Q3	-1.23M
09 Q2	-1M

EPS (USD) · TTM

FITY EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
23 Q3	-0
23 Q2	-0
23 Q1	-0
22 Q4	-0
22 Q3	-0
22 Q2	-0
22 Q1	0
21 Q4	0
21 Q3	-0
21 Q2	-0

Expenses (USD) · TTM

FITY Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
10 Q3	13.09K
10 Q2	13.18K
10 Q1	13.18K
09 Q4	17.89K
09 Q3	4.8K
09 Q2	4.71K
23 Q3	313.36K
23 Q2	101.92K
23 Q1	101.92K
22 Q4	0
22 Q3	0
22 Q2	0
22 Q1	0
21 Q4	0
21 Q3	0
21 Q2	0

Shares Outstanding (USD) · TTM

FITY Shares Outstanding (USD) · TTM by quarter
Period	Shares Outstanding (USD) · TTM
23 Q3	0
23 Q2	0
23 Q1	0
22 Q4	0
10 Q3	0
10 Q2	0
10 Q1	0
09 Q4	0
09 Q3	-6K
09 Q2	4K

Dividends (USD)

FITY Dividends (USD) by quarter
Period	Dividends (USD)
Apr 09	0.01

PE Ratio

FITY PE Ratio by quarter
Period	PE Ratio
Mar 23	415.62
Feb 23	17.74
Nov 22	348.6
Oct 22	348.6
Oct 22	348.6
Jun 07	2.47
Jun 07	2.63
May 07	2.96
May 07	3.29
May 07	3.29
May 07	3.29
May 07	4.27
Apr 07	3.12
Apr 07	3.12
Mar 07	16.6
Mar 07	16.6
Feb 07	16.6
Feb 07	20.16
Feb 07	16.6
Jan 07	17.73
Jan 07	17.73
Dec 06	15.41
Dec 06	9.27
Nov 06	9.59
Nov 06	10.87
Nov 06	9.91
Nov 06	11.51
Nov 06	7.99
Oct 06	8.31
Oct 06	7.67
Oct 06	6.39
Oct 06	7.67
Sep 06	7.67
Mar 06	15.46
Mar 06	20.1
Mar 06	16.49
Mar 06	16.49
Mar 06	15.46
Feb 06	15.46
Feb 06	16.49
Feb 06	21.13
Feb 06	25.77
Jan 06	17.01
Jan 06	18.04
Jan 06	20.1
Jan 06	18.55
Dec 05	18.04

Free Cash Flow Yield

FITY Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Jun 25	11.34%
Jun 25	13.12%
Jun 25	9.76%
Jun 25	10.49%
May 25	15.55%
May 25	14.99%
May 25	22.09%
May 25	20.99%
May 25	12.34%
Apr 25	8.23%
Apr 25	3.82%
Apr 25	10.24%
Apr 25	46.64%
Mar 25	41.97%
Mar 25	27.98%
Mar 25	27.98%
Mar 25	32.29%
Feb 25	32.29%
Feb 25	29.98%
Feb 25	19.99%
Feb 25	83.94%
Jan 25	41.97%
Jan 25	41.97%
Jan 25	34.98%
Jan 25	26.23%
Jan 25	27.98%
Dec 24	20.99%
Dec 24	12.72%
Dec 24	20.99%
Dec 24	24.69%
Nov 24	52.47%
Nov 24	41.97%
Nov 24	41.97%
Nov 24	41.97%
Nov 24	27.98%
Oct 24	38.16%
Oct 24	38.16%
Oct 24	32.29%
Oct 24	18.25%
Sep 24	4.28%
Sep 24	1.76%
Sep 24	1.1%
Sep 24	1.08%
Aug 24	1.45%
Aug 24	2.1%
Aug 24	2.1%
Aug 24	2.8%
Jul 24	2.38%
Jul 24	2.4%
Jul 24	1.4%
Jun 24	4.29%
Jun 24	1.82%
Jun 24	1.87%
May 24	3.19%
May 24	3.65%
May 24	4.87%
May 24	5.21%
Apr 24	3.04%
Mar 24	0.15%
Mar 24	0.1%
Feb 24	0.1%
Feb 24	0.1%
Feb 24	0.1%
Jan 24	0.08%
Jan 24	0.08%
Jan 24	0.2%
Dec 23	0.13%
Dec 23	0.2%
Dec 23	0.14%
Dec 23	0.12%
Dec 23	0.1%
Nov 23	0.1%
Nov 23	0.12%
Nov 23	0.1%
Nov 23	0.2%
Oct 23	0.24%
Oct 23	0.26%
Oct 23	0.13%
Jun 21	-350.54%
Jun 21	-336.46%
Jun 21	-279.73%
Jun 21	-854.89%
May 21	-445.64%
May 21	-382.56%
May 21	-452.86%
Apr 21	-463.45%
Apr 21	-478.74%
Apr 21	-335.12%
Mar 21	-188.27%
Mar 21	-242.84%
Mar 21	-265.97%
Mar 21	-239.71%
Feb 21	-388.77%
Feb 21	-535.33%
Feb 21	-537.05%
Feb 21	-247.5%
Jan 21	-247.5%
Jan 21	-239.37%
Jan 21	-288.9%
Jan 21	-465.44%

Price to Sales

FITY Price to Sales by quarter
Period	Price to Sales
Sep 26	1054.63
Sep 26	1054.63
Sep 26	1581.95
Aug 26	2109.27
Aug 26	1581.95
Aug 26	1581.95
Aug 26	2636.58
Jul 26	2636.58
Jul 26	3163.9
Jul 26	3691.22
Jul 26	3691.22
Jul 26	3163.9
Jun 26	945.1
Jun 26	787.59
Jun 26	787.59
Jun 26	472.55
May 26	472.55
May 26	630.07
May 26	551.31
May 26	708.83
May 26	708.83
Apr 26	1102.62
Apr 26	630.07
Apr 26	630.07
Apr 26	787.59
Mar 26	462.23
Mar 26	462.23
Mar 26	462.23
Mar 26	462.23
Feb 26	462.23
Feb 26	346.67
Feb 26	462.23
Feb 26	577.79
Jan 26	693.35
Jan 26	577.79
Jan 26	462.23
Jan 26	693.35
Jan 26	693.35
Dec 25	2.7
Dec 25	3.09
Dec 25	3.86
Dec 25	5.8
Nov 25	3.48
Nov 25	3.86
Nov 25	5.8
Nov 25	5.02
Oct 25	6.57
Oct 25	5.02
Oct 25	5.8
Oct 25	8.11
Oct 25	10.43
Sep 25	13.14
Sep 25	10.43
Sep 25	12.36
Sep 25	13.14
Aug 25	13.14
Aug 25	10.82
Aug 25	9.66
Aug 25	12.75
Aug 25	12.75
Jul 25	16.23
Jul 25	18.16
Jul 25	21.25
Jul 25	15.07
Jun 25	11.04
Jun 25	9.55
Jun 25	12.83
Jun 25	11.94
May 25	8.06
May 25	8.36
May 25	5.67
May 25	5.97
May 25	10.15
Apr 25	15.22
Apr 25	32.82
Apr 25	12.23
Apr 25	2.69
Mar 25	2.98
Mar 25	4.48
Mar 25	4.48
Mar 25	3.88
Feb 25	3.88
Feb 25	4.18
Feb 25	6.27
Feb 25	1.49
Jan 25	2.98
Jan 25	2.98
Jan 25	3.58
Jan 25	4.77
Jan 25	4.48
Dec 24	5.97
Dec 24	9.85
Dec 24	5.97
Dec 24	5.07
Nov 24	2.39
Nov 24	2.98
Nov 24	2.98
Nov 24	2.98
Nov 24	4.48
Oct 24	3.28

EV/EBITDA

FITY EV/EBITDA by quarter
Period	EV/EBITDA
Jun 24	206.24
Jun 24	483.24
Jun 24	471.2
May 24	277.3
May 24	242.37
May 24	182.16
May 24	170.11
Apr 24	290.55
Jun 07	5.19
Jun 07	5.24
May 07	5.34
May 07	5.45
May 07	5.45
May 07	5.45
May 07	5.75
Apr 07	5.39
Apr 07	5.39
Mar 07	4.63
Mar 07	4.63
Feb 07	4.63
Feb 07	4.92
Feb 07	4.63
Jan 07	4.72
Jan 07	4.72
Dec 06	4.54
Dec 06	3.17
Nov 06	3.21
Nov 06	3.37
Nov 06	3.25
Nov 06	3.45
Nov 06	3.02
Oct 06	3.06
Oct 06	2.98
Oct 06	2.82
Oct 06	2.98
Sep 06	2.98
Sep 06	10.19
Sep 06	10.95
Sep 06	12.46
Aug 06	11.32
Aug 06	12.84
Aug 06	12.65
Aug 06	11.14
Jul 06	10.57
Jul 06	10.95
Jul 06	10.95
Jul 06	12.46
Jun 06	13.98
Mar 06	8.82
Mar 06	11.73
Mar 06	9.47
Mar 06	9.47
Mar 06	8.82
Feb 06	8.82
Feb 06	9.47
Feb 06	12.37
Feb 06	15.28
Jan 06	9.79
Jan 06	10.44
Jan 06	11.73
Jan 06	10.76
Dec 05	10.44

Price/Operating Cashflow

FITY Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
Jun 25	8.82
Jun 25	7.62
Jun 25	10.24
Jun 25	9.53
May 25	6.43
May 25	6.67
May 25	4.53
May 25	4.77
May 25	8.1
Apr 25	12.15
Apr 25	26.21
Apr 25	9.77
Apr 25	2.14
Mar 25	2.38
Mar 25	3.57
Mar 25	3.57
Mar 25	3.1
Feb 25	3.1
Feb 25	3.34
Feb 25	5
Feb 25	1.19
Jan 25	2.38
Jan 25	2.38
Jan 25	2.86
Jan 25	3.81
Jan 25	3.57
Dec 24	4.77
Dec 24	7.86
Dec 24	4.77
Dec 24	4.05
Nov 24	1.91
Nov 24	2.38
Nov 24	2.38
Nov 24	2.38
Nov 24	3.57
Oct 24	2.62
Oct 24	2.62
Oct 24	3.1
Oct 24	5.48
Sep 24	23.35
Sep 24	56.94
Sep 24	90.54
Sep 24	92.68
Aug 24	69.09
Aug 24	47.65
Aug 24	47.65
Aug 24	35.74
Jul 24	41.93
Jul 24	41.69
Jul 24	71.48
Jun 24	23.29
Jun 24	54.81
Jun 24	53.44
May 24	31.38
May 24	27.4
May 24	20.55
May 24	19.18
Apr 24	32.88
Mar 24	665.38
Mar 24	998.07
Feb 24	998.07
Feb 24	998.07
Feb 24	998.07
Jan 24	1188.18
Jan 24	1188.18
Jan 24	499.03
Dec 23	774.59
Dec 23	508.07
Dec 23	724.62
Dec 23	832.9
Dec 23	1041.12
Nov 23	1041.12
Nov 23	832.9
Nov 23	1041.12
Nov 23	499.74
Oct 23	416.45
Oct 23	391.46
Oct 23	749.61

Price to Book

FITY Price to Book by quarter
Period	Price to Book
Dec 07	1.71
Dec 07	1.71
Dec 07	1.8
Dec 07	1.8
Nov 07	2.25
Nov 07	2.02
Nov 07	2.25
Oct 07	2.25
Oct 07	2.47
Oct 07	2.2
Oct 07	2.07
Sep 07	0.53
Sep 07	0.43
Sep 07	0.35
Aug 07	0.35
Aug 07	0.33
Aug 07	0.32
Aug 07	0.39
Jul 07	0.39
Jun 07	0.46
Jun 07	0.39
Jun 07	0.42
May 07	0.47
May 07	0.52
May 07	0.52
May 07	0.52
May 07	0.68
Apr 07	0.5
Apr 07	0.5
Mar 07	0.52
Mar 07	0.52
Feb 07	0.52
Feb 07	0.63
Feb 07	0.52
Jan 07	0.55
Jan 07	0.55
Dec 06	0.48
Dec 06	0.54
Nov 06	0.56
Nov 06	0.64
Nov 06	0.58
Nov 06	0.67
Nov 06	0.47
Oct 06	0.49
Oct 06	0.45
Oct 06	0.37
Oct 06	0.45
Sep 06	0.45
Sep 06	0.52
Sep 06	0.6
Sep 06	0.77
Aug 06	0.64
Aug 06	0.81
Aug 06	0.79
Aug 06	0.62
Jul 06	0.56
Jul 06	0.6
Jul 06	0.6
Jul 06	0.77
Jun 06	0.93
Jun 06	1.08
Jun 06	1.03
Jun 06	1.47
Jun 06	1.61
May 06	1.91
May 06	2.2
May 06	2.88
May 06	2.74
Apr 06	1.47
Apr 06	1.37
Apr 06	1.47
Apr 06	1.47
Mar 06	0.85
Mar 06	1.11
Mar 06	0.91
Mar 06	0.91
Mar 06	0.85
Feb 06	0.85
Feb 06	0.91
Feb 06	1.16
Feb 06	1.42
Jan 06	0.94
Jan 06	0.99
Jan 06	1.11
Jan 06	1.02
Dec 05	0.99
Dec 05	351.12
Dec 05	397.93
Dec 05	366.72
Dec 05	452.55
Nov 05	546.18
Nov 05	624.21
Nov 05	819.28
Nov 05	881.7
Oct 05	1950.66
Oct 05	1716.58
Oct 05	2489.04
Oct 05	3113.25
Sep 05	3284.91
Sep 05	2880.47

No video analysis for this stock yet. Request one from our team.

News: FITY

accessnewswire.com · 26 Aug 2026

Fifty 1 Labs, Inc. Acquires MSK Signal Recovery Product Line to Accelerate Growth in the Peptide and Musculoskeletal Health Market

Acquisition expands Fifty 1 Labs' portfolio with a five-product musculoskeletal recovery platform focused on injury recovery, rehabilitation, connective tissue support, joint health, and peptide-focused research VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY), an emerging biotechnology and health innovation company focused on peptide science, musculoskeletal health, sports performance, injury recovery, rehabilitation, and evidence-driven wellness, today announced that it has acquired a musculoskeletal recovery product line from MSK Signal, a Canadian Biotech Company. The acquired product line includes five key product concepts designed to support Fifty 1 Labs' growth strategy in the peptide and musculoskeletal health markets.

accessnewswire.com · 7 Aug 2026

Fifty 1 Labs Outlines Planned U.S. Telehealth Peptide Services Platform

Model expected to include digital intake, clinician evaluation, prescription routing, monitoring coordination, and subscription-based patient support VANCOUVER, BC / ACCESS Newswire / August 7, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) today provided an overview of its planned U.S. - focused telehealth peptide services platform. The Company intends to develop a patient-facing service model that complements its peptide science and commercialization strategy while remaining separate from investigational clinical-development programs.

accessnewswire.com · 10 Jul 2026

Fifty 1 Labs Announces Strategic Evolution into Peptide Biotechnology and Telehealth

Company outlines dual platform spanning peptide R&D, AI-enabled discovery, and planned U.S. telehealth peptide services VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) (the "Company" or "Fifty 1 Labs") today announced that it is positioning itself as a peptide biotechnology and telehealth company focused on advancing peptide science, musculoskeletal ("MSK") health, recovery, and evidence-driven product innovation. The Company's emerging strategy integrates three complementary areas: peptide research and development, AI-enabled discovery workflows, and a planned U.S.-focused telehealth peptide services platform.